Genbioma specializes in research and development services to develop novel, science-based solutions for human health in the field of probiotics and other bioactive compounds.
Our main partners are the dietary supplement and food industries.
At Genbioma, we create probiotic & postbiotic supplements using objective, measurable criteria that are based on extensive research and trials.
Our strains collection is supported by scientific data, and we use scientifically documented and patented probiotic strains. Additionally, our supplements undergo pre-clinical and clinical trials to ensure their safety and effectiveness. Our probiotic and postbiotic supplements are ready to go, making it easy for you to incorporate them into your daily routine.
Genbioma develops its own probiotic & postbiotic supplements based on objective, measurable criteria, which are the result of research and/or trials on:
Genbioma aims to be a reference in the Premium Probiotics & Postbiotics market
pA1c(R) & pA1c(R)HI
Probiotic pA1c(R) & Postbiotic pA1c(R)HI are the first Genbioma´s benchmark strain for nutrition brands. The innovation is based on scientific dossiers
Reglubetic(R) & Reglubetic(R)HI
Probiotic Reglubetic(R) and Postbiotic Reglubetic(R)HI are a daily oral probiotic supplements.
The solution is a breakthrough in microbiome science based on our exclusive pA1c(R) strain.
Our probiotic contains a unique strain formulation that is exclusively patented and cannot be found in any other probiotic product available in the market.
Ongoing clinical trials and real-life tests in different sites within the EU. If you want to join us, send an email to email@example.com.
Genbioma is a research platform for Microbiome based solutions (probiotics and postbiotics).
The research includes the selection, identification, scale-up, and production of our patented strain collection, in vitro and in vivo pre-clinical studies in animal models as well as clinical trials in humans.
Through leading international strategic partners and investment in R&D, Genbioma develops probiotics and postbiotics on an industrial scale and provides a solid scientific base with publications in high-impact scientific journals. The company has a clear orientation towards the international market.
5 scientific papers published by international prestigious journals (Q1) since 2022, including Diabetologia. XX communications at international scientific congresses since 2022, including XX selections by the three main global diabetes congresses: American Diabetes Association (ADA), etc
EmprendeXXI en NAVARRA
Premio Emprende | Alimentaria FoodTech
Scale the Impact
SELLO PYME INNOVADORA